Cardiovascular disease burden in patients with urological cancers:The new discipline of uro-cardio-oncology
作者机构：Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular DiseaseDepartment of CardiologyTianjin Institute of CardiologySecond Hospital of Tianjin Medical UniversityTianjinChina School of Nursing and Health StudiesHong Kong Metropolitan UniversityHong KongChina
出 版 物：《Cancer Innovation》 (肿瘤创新（英文）)
年 卷 期：2024年第3卷第2期
页 面：28-44页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：Tianjin Key Medical Discipline(Specialty)Construction Project,Grant/Award Number:TJYXZDXK-029A National Natural Science Foundation of China,Grant/Award Numbers:82170327,82370332 Research Impact Fund of the Hong Kong Metropolitan University,Grant/Award Number:RIF/2022/2.2
主 题：anticancer therapy cardiovascular toxicity mechanism multidisciplinary management urological cancer
摘 要：Cancer remains a major cause of mortality worldwide,and urological cancers are the most common cancers among *** therapeutic agents have been used to treat urological cancer,leading to improved survival for ***,this has been accompanied by an increase in the frequency of survivors with cardiovascular complications caused by anticancer medica***,we propose the novel discipline of uro-cardio-oncology,an evolving subspecialty focused on the complex interactions between cardiovascular disease and urological *** this comprehensive review,we discuss the various cardiovascular toxicities induced by different classes of antineoplastic agents used to treat urological cancers,including androgen deprivation therapy,vascular endothelial growth factor receptor tyrosine kinase inhibitors,immune checkpoint inhibitors,and *** addition,we discuss possible mechanisms underlying the cardiovascular toxicity associated with anticancer therapy and outline strategies for the surveillance,diagnosis,and effective management of cardiovascular compli***,we provide an analysis of future perspectives in this emerging specialty,identifying areas in need of further research.
维普期刊数据库